Evogene Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Evogene Ltd., a foreign private issuer, for the month of March 2014. The report discloses a corporate governance decision regarding director compensation made on March 18, 2014.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a non-financial corporate action.
Material Changes
On March 18, 2014, the Board of Directors unanimously resolved that all directors are entitled to receive fees for their participation in Board and committee meetings. These fees must fall within the range specified by the Israeli Companies Law Regulations (Rules Regarding the Compensation and Expenses of an External Director), 5760-2000.
Guidance, Outlook, and Management Commentary
- The approved compensation structure is consistent with the Company's Compensation Policy, which was approved by shareholders on March 11, 2014.
- The resolution explicitly excludes equity compensation (such as options to purchase ordinary shares), which may be granted separately under the Compensation Policy.
- No financial guidance, risk factors, or unusual items were disclosed in this specific filing.
Key Facts for Investor Verification
- Verify the specific fee amounts approved for directors against the limits set by the Israeli Companies Law Regulations.
- Confirm the details of the Compensation Policy approved by shareholders on March 11, 2014.
- Monitor future filings for any separate grants of equity compensation to directors, as this filing excludes such items.